Haemonetics says FDA clears vascular closure device

Haemonetics announced FDA approval for its PerQseal Elite device, which seals arterial openings in heart and vascular procedures. The company acquired the technology via its 2026 purchase of Vivasure Medical. Shares rose 1.2% in extended trading. Additional clinical data will be presented at an upcoming conference.

Original reporting
Published Oct 19, 2026, 9:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 19, 2026, 9:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Haemonetics says FDA clears vascular closure device — source image
Decision brief

The 30-second read

$HAEBullishMed
01

Why it matters

Regulatory clearance validates the acquisition and may accelerate revenue from the new device.

02

Market read

First‑report FDA approval provides a fresh catalyst for Haemonetics, likely supporting a modest price gain.

03

What to watch

Potential competition from established closure devices and pricing pressure.

Relevance 8/10Novelty 8/10Timing: after-hours reaction

Background

Haemonetics acquired Vivasure Medical in Jan 2026, gaining the technology behind PerQseal Elite.

Company-level read

Ticker impact

$HAEBullishHigh confidence
Context

FDA cleared Haemonetics' PerQseal Elite vascular closure device, a new product approval.

Expected impact

modest upside as market prices in the regulatory clearance

Evidence & confidence

First report of FDA clearance; small but positive catalyst for a mid‑cap medical device maker.

Market effects

May lift sentiment for vascular closure and broader interventional device sector.

U.S. medical device market sees a new cleared product.

Limited to device manufacturers; no broad macro effect.

Counterpoint

Approval impact could be muted if adoption is slow or reimbursement issues arise.

Key entities

  • Haemonetics

    Medical technology firm providing blood management and interventional products.

  • Vivasure Medical

    Ireland‑based developer of the PerQseal Elite device.

Related articles

$HAEMed

Haemonetics receives CE mark for vascular closure system

Haemonetics (NYSE:HAE) received CE Mark certification for its VASCADE MVP XL venous vascular closure system, allowing EU and other market sales. The device is designed for larger sheath procedures and uses more collagen than its predecessor. The company's portfolio includes other CE-marked vascular closure systems. According to the company, the product has driven growth in the U.S. Interventional Technologies business.

$HAEHighAI 8/10

Haemonetics Q2 Earnings Call Highlights

Haemonetics (HAE) reported 18% organic plasma revenue growth in Q2, raising its full-year apheresis revenue growth forecast. MedSurg revenue grew 6%, and margins improved slightly. The company plans increased capital expenditures for capacity expansion. HAE reaffirmed mid-single-digit MedSurg growth for fiscal 2027, with new product launches in early stages.

$HAEMedAI 8/10

Haemonetics Corp (HAE) (Q2 2027) Earnings Call Highlights: Raised Guidance and Expanded

Haemonetics Corp (HAE) reported Q2 2027 earnings, raising guidance but lowering operating margin expansion due to higher costs and investments. CEO Christopher Simon highlighted a multiyear growth opportunity with CSL, though margin contributions are expected in fiscal 2028. The company faces near-term pressures from elevated production and freight costs, with second-half margin expansion weighted toward Q4.

$HAEHighAI 8/10

Haemonetics Corporation Q2 2027 Earnings Call Summary

Haemonetics reported Q2 2027 plasma growth of 18%, driven by Persona PLUS adoption. CSL relationship expansion and FDA approval for PerQseal Elite were highlighted. Revenue guidance raised to 6-9%, but margin expansion lowered due to supply chain costs. Free cash flow conversion expected to exceed 80%.